Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report1
- Aducanumab for Alzheimer’s disease: effectiveness and value : final evidence report and meeting summary1
- Gene therapies for sickle cell disease: final evidence report1
- Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report1
- Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report1
- Observational real-world evidence update: prophylaxis of hereditary angioedema with Takhzyro and C1 inhibitors : effectiveness and value1
- Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- Unsupported price increase report: 2020 assessment1